Elekta (OTCMKTS:EKTAY) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Elekta (OTCMKTS:EKTAY) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Elekta Stock Up 0.5%

Shares of Elekta stock opened at $4.99 on Tuesday. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -31.16 and a beta of 1.01. Elekta has a twelve month low of $4.35 and a twelve month high of $6.93. The company has a current ratio of 0.87, a quick ratio of 0.68 and a debt-to-equity ratio of 0.47. The business’s 50 day simple moving average is $5.32 and its 200-day simple moving average is $5.86.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings data on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. The business had revenue of $521.00 million during the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%. Equities research analysts forecast that Elekta will post 0.43 earnings per share for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.